Share on StockTwits

Mast Therapeutics (NASDAQ:MSTX) released its earnings data on Monday. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06), AnalystRatingsNetwork reports.

A number of research firms have recently commented on MSTX. Analysts at Laidlaw initiated coverage on shares of Mast Therapeutics in a research note on Wednesday, August 6th. They set a “buy” rating and a $2.50 price target on the stock. Analysts at ISI Group initiated coverage on shares of Mast Therapeutics in a research note on Monday, June 16th. They set a “reduce” rating on the stock.

Shares of Mast Therapeutics (NASDAQ:MSTX) remained flat at $0.60 during trading on Monday. 161,522 shares of the company’s stock traded hands. Mast Therapeutics has a one year low of $0.40 and a one year high of $1.10. The stock’s 50-day moving average is $0.61 and its 200-day moving average is $0.68. The company’s market cap is $68.5 million.

Mast Therapeutics, Inc, formerly ADVENTRX Pharmaceuticals, Inc, is a development-stage company biopharmaceutical company focused on developing product candidates.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.